Drugs / SK-NK Cell Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07435701 | Jan 2026 overdue | ovarian cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SK-NK Cell Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07435701 ↗ |
| Modality | Cell therapy | “The treatment involves the direct infusion of allogeneic, highly activated Natural Killer (NK) cells (SK-NK) into the abdominal cavity .” NCT07435701 ↗ |
| Route | Other | “via intraperitoneal perfusion” NCT07435701 ↗ |